Takeda gets financial support from US to develop Zika vaccine
The US Biomedical Advanced Research and Development Authority (BARDA) has selected the company’s vaccine business unit to develop an inactivated, adjuvanted, whole Zika virus vaccine. Takeda will receive
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.